StockMarketWire.com - AstraZeneca said its type-2 diabetes drug on top of standard care showed a reduction in both the incidence of cardiovascular death and the worsening of heart failure in patients with and without type-2 diabetes.
The trial of Farxiga (dapagliflozin) on top of standard of care showed a 30% decrease in the risk of experiencing a first episode of worsening heart failure and an 18% decrease in the risk of dying from cardiovascular causes, the company said.
The trial results also showed a significant improvement in patient reported outcomes measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score and a nominally significant reduction in all-cause mortality by 17% (7.9 versus 9.5 patients with an event per 100 patient-years) in favour of Farxiga.
'Farxiga is well established in the treatment of type-2 diabetes, and these exciting new findings offer clinically meaningful insights into the potential of the medicine to reduce the burden of heart failure in patients with and without type-2 diabetes. We are proud to be contributing to the scientific body of evidence during the ESC Congress 2019,' said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D.
The update comes after the topline results announced last month showed DAPA-HF had met the primary endpoint.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.